Posted in | News | Mineral Sands | Lithium

Critical Elements Reports Successful Completion of Pilot Plant Trials

Critical Elements Corporation (the "Corporation" or "Critical Elements") (TSX VENTURE:CRE)(OTCQX:CRECF)(FRANKFURT:F12) is pleased to announce that it has successfully completed its pilot plant trials. The program confirmed the suitability and robustness of the beneficiation plant design. The outstanding results yielded lithium concentrate grades of up to 6.56% and recoveries of up to 83.4%. Results obtained in pilot plant testing demonstrate very good understanding of the processing of the mineralized material, and the commercial plant should generate results similar to the locked cycle tests with the optimized equipment.

Locked cycle tests returned outstanding results, with a lithium concentrate grade of 6.65% Li2O and recoveries of up to 89.7%. Tantalite recoveries were 48.1% for Rose and 64.4% for Rose South, respectively, with grades of 1.44% and 2.39% Ta2O5, respectively.

The trials also included testing of low iron content mineralized material suitable for higher-value Glass and Ceramics applications (Spodumene Tech Grade).

"I am very excited about our pilot plant results, which highlight the low risk profile of the project. The lithium market is desperately looking for new, reliable, and sustainable suppliers like Critical Elements, as yearly demand for lithium carbonate is expected to grow from 200,000 mt, to more than 600,000 mt", said Dr. Steffen Haber, President.

"Helm congratulates Critical Elements on the successful recovery of this high quality spodumene. Our customers are looking forward to when we can supply their needs from the Rose Mine", said Oliver Leptien, Executive Manager, Derivatives Business Unit of Helm AG.

Lithium recoveries improved as the trial progressed, indicating an increased understanding of the process, which resulted in adjustments being made to the operation. The proposed plant design includes simple grinding, and industry-standard flotation circuits, and uses magnetic and gravity separation to upgrade the Spodumene and Tantalite ore.

Pilot plant trials were conducted in 12- and 48-hour phases at a rate of 250 kg/h on material from two different zones of the deposit, Rose and Rose South. Initial trials were performed during a 12-hour run to establish operating conditions, after which a 48-hour run was conducted to produce a concentrate and test the selected circuit design.

The series of pilot runs conducted using the Rose and Rose South materials confirmed the results with respect to lithium grade and recovery. The trials outlined results of up to 6.41% Li2O with recovery up to 83.4% for Rose, and 6.56% Li2O with recovery up to 81.9% for Rose South. With respect to tantalum, adjustments were made to the Ta recovery unit and an additional unit was added to improve recovery. The final four runs showed Ta recovery up to 69.1%. The pilot plant work indicates that similar recoveries can be obtained for tantalum as in laboratory testing, and the tantalum will be further concentrated by gravity or flotation, from a grade of 1-2% Ta2O5 up to 25% Ta2O5.

"We are very enthusiastic about these recent results, which confirm the high-grade concentrate, and robust recovery profile of our project," said Jean-Sébastien Lavallée, Chief Executive Officer of Critical Elements Corporation. "The Rose lithium-tantalum project has always returned lithium recoveries and grades that were above industry standards. These results have now been confirmed at the pilot plant scale."

Jean-Sébastien Lavallée (OGQ #773), geologist, shareholder and Chief Executive Officer of the Company and a Qualified Person under NI 43-101, has reviewed and approved the technical content of this release.

Source: http://www.cecorp.ca/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.